Please provide your email address to receive an email when new articles are posted on . Significant improvements in clinical remission rates were observed at 12 weeks with risankizumab vs. placebo (20 ...

A systematic review of trial data finds that people who experience remission soon after induction therapy are 65% likelier to see long-term benefit than those who have only a partial response. The ...

Please provide your email address to receive an email when new articles are posted on . At the end of induction, 56% of patients treated with subcutaneous guselkumab vs. 21% on placebo achieved ...

Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial Homoharringtonine (HHT) is commonly used for the treatment of Chinese ...

Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Forty-three evaluable patients with common/pre-B (n ...

Three yellow capsules on blueish, reflective background. Avacopan plus rituximab offers a superior remission rate at 52 weeks and lower risk of relapse compared with prednisone taper plus rituximab, ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis factor (TNF) blockers, new FDA approvals, problems with placebos, and ...

"The CareRA2020 trial did not completely solve the unmet need of patients responding insufficiently to conventional initial therapy for early RA, but it provides opportunities to further optimize the ...

Even in nonproliferative class 1-2 LN, glucocorticoid monotherapy may be insufficient to prevent long-term renal damage. Combination therapy should be considered. Patients with class 1-2 lupus ...